In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer post-CDK4/6 inhibitor, gedatolisib combinations significantly extended progression-free survival versus fulvestrant. The gedatolisib triplet (gedatolisib + palbociclib + fulvestrant) delivered a median PFS of 9.3 months versus 2.0 months (HR 0.24; p<0.0001), while the gedatolisib doublet (gedatolisib + fulvestrant) achieved 7.4 months versus 2.0 months (HR 0.33; p<0.0001). Objective response rates were 31.5% for the triplet and 28.3% for the doublet versus 1% for fulvestrant, with median durations of response of 17.5 and 12.0 months, respectively. Grade ≥3 treatment-related events were dominated by neutropenia in the triplet (52.3% grade 3; 10.0% grade 4), absent in the doublet, with stomatitis (19.2% triplet; 12.3% doublet) and low rates of hyperglycemia (2.3% in both) notable. Discontinuations due to TRAEs were 2.3% (triplet) and 3.1% (doublet). The results are now published in the Journal of Clinical Oncology, and the FDA has granted Priority Review to the gedatolisib NDA with a PDUFA goal date of July 17, 2026. The core development is clear: a pan-PI3K/mTORC1/2 inhibitor has produced a robust, statistically persuasive PFS benefit in a PIK3CA wild-type population where approved PAM inhibitors are largely mutation-restricted or deliver modest benefit. The trial, which randomized PIK3CA wild-type patients to triplet, doublet, or fulvestrant, positions gedatolisib as a potential biomarker-agnostic option in a post-CDK4/6 setting where sequencing has been unsettled. Strategically, Celcuity is aiming into the largest remaining gap in HR+/HER2- after CDK4/6 failure: patients without actionable PI3K/AKT/PTEN alterations who are not candidates for alpelisib or capivasertib-based regimens. The doublet’s performance is central to that bid. While the triplet yields a 1.9-month PFS increment over the doublet, the hematologic burden appears driven by palbociclib, sharpening the trade-off between incremental efficacy and operational complexity. If regulators accept a flexible label that encompasses both regimens, commercial adoption may coalesce around the doublet for its efficacy-to-tolerability ratio, with the triplet reserved for select patients where added PFS justifies the monitoring intensity. For sites and CROs, the signal reduces reliance on biomarker gating and could simplify screening pipelines in second line and beyond. Operationally, the triplet necessitates tighter CBC surveillance and dose-modification workflows typical of CDK4/6 programs, alongside stomatitis management; the doublet lowers hematologic risk but still requires mucositis vigilance. Notably, hyperglycemia rates were low compared with PI3Kα inhibitors, potentially easing metabolic monitoring burdens and patient selection constraints. For sponsors designing post-CDK4/6 programs, VIKTORIA-1 reopens the question of CDK4/6 continuation versus switch, offering a data-backed pathway for both approaches. Regulators, meanwhile, will scrutinize comparator relevance and external generalizability, as the fulvestrant control median PFS of 2.0 months underscores a heavily pretreated, fast-progressing population. Looking ahead, the key variables are label scope and positioning. Whether the FDA endorses both doublet and triplet—and whether any biomarker language is imposed—will dictate uptake and payer dynamics. Read-through from VIKTORIA-2 in first line could further reshape sequencing if efficacy translates earlier with manageable toxicity. OS and quality-of-life data will be influential for guidelines and payer coverage. On the ground, adoption will hinge on how efficiently sites can operationalize stomatitis prophylaxis and hematology monitoring and whether visit intensity aligns with real-world capacity. Watch for final labeling, any postmarketing commitments around safety monitoring, and how competitors recalibrate with AKT and PI3Kα strategies in a market that may be shifting toward broader, mutation-agnostic PAM inhibition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
